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The bone matrix is maintained functional through the combined action of bone resorbing osteoclasts and
bone forming osteoblasts, in so-called bone remodeling units. The coupling of these two activities is crit-
ical for securing bone replenishment and involves osteogenic factors released by the osteoclasts. How-
ever, the osteoclasts are separated from the mature bone forming osteoblasts in time and space.
Therefore the target cell of these osteoclastic factors has remained unknown. Recent explorations of
the physical microenvironment of osteoclasts revealed a cell layer lining the bone marrow and forming
a canopy over the whole remodeling surface, spanning from the osteoclasts to the bone forming osteo-
blasts. Several observations show that these canopy cells are a source of osteoblast progenitors, and
we hypothesized therefore that they are the likely cells targeted by the osteogenic factors of the osteo-
clasts. Here we provide evidence supporting this hypothesis, by comparing the osteoclast-canopy
interface in response to two types of bone resorption inhibitors in rabbit lumbar vertebrae. The bis-
phosphonate alendronate, an inhibitor leading to low bone formation levels, reduces the extent of canopy
coverage above osteoclasts. This effect is in accordance with its toxic action on periosteoclastic cells. In
contrast, odanacatib, an inhibitor preserving bone formation, increases the extent of the osteoclast-can-
opy interface. Interestingly, these distinct effects correlate with how fast bone formation follows resorp-
tion during these respective treatments. Furthermore, canopy cells exhibit uPARAP/Endo180, a receptor
able to bind the collagen made available by osteoclasts, and reported to mediate osteoblast recruitment.
Overall these observations support a mechanism where the recruitment of bone forming osteoblasts from
the canopy is induced by osteoclastic factors, thereby favoring initiation of bone formation. They lead to a
model where the osteoclast-canopy interface is the physical site where coupling of bone resorption to
bone formation occurs.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Bone remodeling consists of bone resorption by osteoclasts fol-
lowed by bone formation by osteoblasts. The mechanism ensuring
the restoration of resorbed bone is gaining increasing attention
because malfunction of this mechanism contributes to bone lossand fractures. An important concept is that osteoclasts are part
of this mechanism, probably through the release of pro-osteoblas-
tic factors [1–3]. The basis of this concept is that general inhibitors
of osteoclasts, such as alendronate (ALN), a bisphosphonate, lead to
decreased bone formation, whereas inhibition restricted to their
resorptive activity sustains or even increases bone formation
[2,4,5] while increasing the number of non-resorbing osteoclasts
[6–9]. An example of the latter inhibitors is odanacatib (ODN), a
selective inhibitor of cathepsin K, the main proteinase degrading
collagen during bone resorption. This compound is presently in a
phase III clinical trial for the treatment of osteoporosis.
Importantly, osteoclasts and bone forming osteoblasts are sep-
arated in time and space during the remodeling cycle, and it is still
not understood how the osteoclast-derived factors make osteo-
blasts restitute locally the bone matrix [1]. We previously
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the immediate osteoclast surroundings, thereby promoting the
reversal phase of the remodeling cycle, which is critical for recruit-
ment of osteoprogenitors and initiation of bone formation [10,11].
In line with this hypothesis, we found that ODN induces a shorter
reversal phase, higher osteoblast recruitment, and an increase in
osteoclast surface in ovariectomized rabbits, whereas ALN did
not show these responses [7]. Accordingly, a previous analysis of
the same rabbits, showed that ODN had a positive effect on bone
formations rate, whereas ALN decreased bone formation rates
[5]. Amongst the cells which may be targeted by osteoclasts are
reversal cells on the bone surface [7,10,11], canopy cells at the
interface of the bone marrow and the bone remodeling site
[12–14], and vasculature-associated cells at the canopy-marrow
interface [12,15]. All belong to the osteoblast lineage and may
serve as progenitors of bone forming osteoblasts [11]. Particular
attention on the likely participation of canopy cells in this process
is drawn by decreased bone formation in disease situations of
canopy deﬁciency [12,14,16]. Here we hypothesized that canopy
cells might be the unidentiﬁed partners of the osteoclasts, allowing
them to exert their anabolic role. We tested this hypothesis by
extending the analyses of our earlier study performed in ovariecto-
mized rabbits, where the extent of osteoclasts surfaces, the rever-
sal phase, and bone formation were promoted by ODN, but not by
ALN [5,7]. The question we asked was whether the distinct effects
of ODN and ALN we reported on these parameters would coincide
with distinct effects of ODN and ALN on the osteoclast-canopy
interface, thereby suggesting a causal relationship.
2. Materials and methods
2.1. Immunohistochemistry, histomorphometry and electron
microscopy
The present study is a follow-up of our recent study reporting
the effects of ALN and ODN on post-osteoclastic events inFig. 1. Proximity of osteoclasts and canopy cells as it appears in histological sections. (A
the vertebral trabecular bone of ODN-treated OVX rabbits as it appears by using Masson
right), and electron microscopy (lower). Note the close proximity of vascular structures (bl
(asterisk), and canopy cells is frequently lost in ALN-treated OVX rabbits as illustrated by
Arrows in (A) and (B) indicate reversal cells. Scale bar: 20 lm, except for A, lower panel:ovariectomized rabbits [7]. We used the same lumbar vertebrae
from the four experimental groups: sham-operated, ovariecto-
mized treated with vehicle, ALN, or ODN [7]. For immunohisto-
chemical staining, parafﬁn sections (3.5 lm thick) from the
second lumbar vertebrae were processed as described [7].
Immunostaining for the endocytic collagen receptor urokinase
plasminogen activator receptor-associated protein (uPARAP/Endo
180), was performed using a monoclonal mouse antibody,
2h9F12, [17] which was detected with a polymeric alkaline phos-
phatase conjugated system (Bright Vision, Immunologic, Duiven,
Holland) and visualized by liquid permanent red (DakoDenmark
A/S, Glostrup, Denmark). Negative controls were performed by
using an isotype-matched mouse control immunoglobulin (IgG1,
MOPC-21, Ab18443, Abcam). Sections were counterstained with
Mayer’s haematoxylin and mounted.
Histomorphometric parameters were assessed in the trabecu-
lar bone of Masson-Goldner trichrome-stained sections (6 lm
thick) prepared from the plastic-embedded fourth lumbar verte-
brae as described by Jensen et al. [7]. The parameters included
the proportion of bone surface covered by osteoclast (Oc.S),
reversal (Rv.S), and osteoid surface (OS), where each parameter
was determined in relation to the presence or absence of a
canopy [12,14–16]. Reversal surfaces were deﬁned as eroded
surfaces without osteoclasts. Eroded surfaces were identiﬁed
through visualization of broken lamellae in polarized light. Cano-
pies were deﬁned as a continuous layer of elongated cells lining
the bone marrow and separated from the bone matrix by osteo-
clasts, reversal cells, or osteoblasts, and sometimes by a lumen
[12,13] (Fig. 1A, yellow arrowheads). For every single hit on
reversal perimeters, the presence of both an osteoclast and oste-
oid in the vicinity was recorded. Vicinity was deﬁned as being
within the same 2D remodeling unit as the reversal surface itself
[7]. All measurements were done blinded with respect to sham,
OVX, ALN, and ODN treatment.
Samples for electron microscopy were prepared and analyzed as
previously described [15].) Association between osteoclasts (asterisk) and canopy cells (yellow arrowheads) in
-Goldner trichrome (upper left), uPARAP immunohistochemical staining (red) (upper
ack arrowheads) and canopies (upper panels). (B) The association between osteoclasts
Masson-Goldner trichrome (left) and uPARAP immunohistochemical staining (right).
2 lm.
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All parameters for each group were tested for normality using
the D’Argostino–Pearson omnibus test. Overall comparisons of
the groups were performed using one-way analysis of variance
(ANOVA) when data allowed for parametric statistics, whereas
the Kruskal–Wallis test was applied when non-parametric statis-
tics were needed. The post-test for individual comparison of
groups was the Tukey–Kramer test for parametric analyses and
Dunn’s multiple comparison test for non-parametric analyses.
The relationship between two parameters was analyzed by a
two-sided Chi-square test. p values lower than 0.05 were consid-
ered statistically signiﬁcant. The speciﬁc analysis used for the indi-
vidual measurements are indicated in the respective ﬁgure legend.
All statistical analyses were performed with GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA, USA).3. Results and discussion
3.1. Differences in proximity of osteoclasts to canopies in ODN- and
ALN-treated rabbits
The analysis of bone remodeling sites in vertebrae of OVX rab-
bits treated with ODN revealed the typical features emphasized in
our previous report [7]: osteoclasts frequently associated with
demineralized collagen in the resorption zone, and in close prox-
imity with the reversal cells (Fig. 1). The latter cells could be clearly
visualized both in Masson staining and through immunoreactivity
of uPARAP/Endo 180, the endocytic collagen receptor present in
osteoblast lineage cells and involved in collagen uptake and bone
formation [18,19]. In addition, the present analysis identiﬁed aFig. 2. Effect of ODN and ALN treatment on the canopy-bone surface interface. The trabe
left graphs), reversal surfaces (Rv.S, middle graphs), and osteoid (OS, right graphs). (A) The
OVX rabbits treated with vehicle (Veh), alendronate (ALN), or odanacatib (ODN). (B) Th
shown for each group as percentage of total bone surface. In (A) and (B), each symbol re
median except for A, left, where the mean values are indicated. Overall differences were
middle and right: ns) or ANOVA (A, left: p < 0.0001). Post-test for pairwise comparisons:layer of elongated cells between the osteoclasts and the bone mar-
row, which appeared identical with the so-called canopy, recently
identiﬁed at remodeling sites of human cancellous bone
[12–14,16] (Fig. 1A). These canopy cells were visible through Mas-
son staining (Fig. 1A, upper left panel) and were clearly revealed
through uPARAP/Endo 180 immunoreactivity (Fig. 1A, upper right
panel), as well as by using electron microscopy (Fig. 1A, lower
panel). Vascular spaces containing erythrocytes were also identi-
ﬁed at the bone marrow side of these canopies, as typically
reported in human cancellous bone [12,15]. The same analysis
performed on remodeling sites of ALN-treated bones showed also
osteoclasts and reversal cells as previously described [7], but can-
opy cells were most often not detected, whether through Masson
or uPARAP staining (Fig. 1B). The qualitative histological analysis
thus suggests a difference of effect of ODN and ALN on canopy
coverage.3.2. Quantiﬁcations of the osteoclast-canopy interface in ODN- and
ALN-treated rabbits
Next, we systematically quantiﬁed the degree of coverage of
osteoclasts by canopy cells in ODN and ALN-treated rabbits, com-
pared to control conditions. Fig. 2A shows that treatment of OVX
rabbits with ALN resulted in a signiﬁcant reduction in the propor-
tion of osteoclasts covered by canopy cells, whereas ODN did not
do so. In contrast, the degree of coverage of reversal and osteoid
surfaces by canopies was similar and high after ALN and ODN
treatment. This indicates that the effect of ALN on reducing canopy
coverage is osteoclast-speciﬁc. The speciﬁcity of this effect is in
line with the observation of Coxon et al. [20] that osteoclasts re-
lease ALN from the bone matrix, and after transcytosis, allow itscular bone surfaces (BS) were sorted according to the presence of osteoclasts (Oc.S,
proportion of each of these surfaces covered by a canopy was assessed in sham and
e total length of the interface between canopies and each of these bone surfaces is
presents the measurement obtained in one rabbit. The horizontal bars indicate the
analyzed by the Kruskal–Wallis test (A, middle and right: ns; B, left: p < 0.0001; B,
⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
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the osteoclast. In this respect, it is interesting to note that canopy
cells are positioned along the basolateral secretory domain of
osteoclasts [21–23], and appear thus particularly exposed to ALN
release [20]. If the canopy is a source of osteoprogenitors, it makes
sense that ALN-induced damage of the canopy cells would harm
osteoblast recruitment, delay initiation of matrix deposition, and
slow down bone formation as reported in the previous studies per-
formed on the same rabbits [5,7]. This is consistent with the view
that osteoclasts appear involved to some extent in the negative ef-
fect of bisphosphonates on bone formation [24]. The same scenario
has been shown in a series of other situations of canopy deﬁciency,
such as multiple myeloma, Cushing’s syndrome, and post-meno-
pausal osteoporosis [12,14,16].
Conversely, in situations where the canopy is preserved, the po-
sition of the canopy cells is ideal for exposure to the osteogenic
products released through the basolateral secretory domain of the
osteoclasts. This vesicular release was proposed to play a role in
coupling bone resorption and formation [25]. Onemay therefore ex-
pect that the total length of the osteoclast-canopy interface may
inﬂuence the efﬁciency of osteoblast recruitment during the
reversal phase. Interestingly in this respect, Fig. 2B shows that
ODN treatment resulted in a fourfold increase in the total length
of osteoclast-canopy interfaces, whereas ALN had no effect on this
parameter. Also when comparing the effect of ODN and ALN on
the length of the canopy-bone surface interface at various phases
of the remodeling cycle, we notice that it is above the osteoclasts
that they show the biggest differences, and that this is the only place
where these differences are statistically signiﬁcant (Fig. 2B). Thus
we found that ODN and ALN, which in the previous studies on the
same rabbitswere reported to affect differently osteoblast densities,
bone formation, and bone density [5,7], also affect differently the
interface between osteoclasts and canopies, but not the interaction
of the canopy with other features, suggesting therefore a critical
partnership between osteoclasts and canopies.3.3. Relation between the extent of the osteoclast-canopy interface and
the length of the reversal phase in ODN- and ALN-treated rabbits
Next we reasoned that the way the extent of osteoclast-canopy
interface may affect bone formation would be reﬂected by the
length of the reversal phase, which is connecting osteoclastic
resorption with osteoblastic formation [7,10]. As an indicator of
the length of the reversal phase, the proximity of reversal surfacesFig. 3. Relation between the extent of osteoclast-canopy interface and the length of the re
(Rv.S) to both osteoclasts (Oc.S) and osteoid surfaces (OS) was assessed in sham and OVX
expressed as the percentage of reversal surface hits with both Oc.S and OS in the vicinity
were analyzed by ANOVA: p = 0.0011. Post-test for pairwise comparisons: ⁄⁄p < 0.01. (B)
proximity of reversal surfaces to both osteoclasts and osteoid surfaces shown in (A) was p
shown in Fig. 2. Based on the distribution pattern of the measurements we categorized th
canopy (limit put at 3%) and a high or low extent of Rv.S in proximity of Oc.S and OS (lim
the two variables was analyzed by a Chi-square test: p = 0.0022. In (A) and (B), each symto both osteoclast and osteoid was recorded. Fig. 3A shows that
reversal surfaces were twice as frequently in the vicinity of both
osteoclasts and osteoid surfaces in ODN versus ALN treatment,
thus indicating that compared to ALN, ODN treatment leads to a
faster initiation of osteoid deposition after the departure of the
osteoclast. Furthermore, plotting the proximity of reversal surfaces
to both osteoclast and osteoid surfaces against the total length of
osteoclast-canopy interface clearly shows that the shorter osteo-
clast-canopy interfaces measured in the ALN group correspond
with a slower initiation of bone formation, whereas longer osteo-
clast-canopy interfaces of the ODN group correspond to a faster
initiation of bone formation (Fig. 3B). The overall pattern of the
plot suggests a positive correlation between length of osteoclast-
canopy interface and rate of initiation of bone formation up to a
plateau, which is reached upon treatment with ODN.3.4. The osteoclast-canopy partnership coupling bone resorption to
bone formation
There is compelling evidence for an involvement of osteoclasts
in coupling of bone resorption to formation. This evidence includes
observations on low bone formation under osteoclast-poor condi-
tions [26,27], as well as preserved/increased bone formation in
osteoclast-rich conditions, as seen with ODN treatment. Other
examples of the latter are suppression of the function of c-Src or
the chloride channel-7 (ClC-7), which all coincide with well per-
forming bone formation [2,6,8,9]. Intensive search to identify the
mechanism behind the coupling activity of the osteoclast has led
to the identiﬁcation of a number of anabolic factors released by
the osteoclast, as reviewed by Henriksen et al. [1]. These factors in-
clude for example TGF-beta, IGF, S1P, TRAcP, as well as EphrinB2,
and are considered to be the actual factors coupling bone resorp-
tion and formation. However, an important information which
has been missing for understanding the mechanism behind these
coupling signals is the identity of the target cell of these osteoclast
products [1].
There is also another line of research showing evidence for an
involvement of bone remodeling compartment canopies in
coupling bone resorpion to formation. First, situations of canopy
deﬁciency, such as multiple myeloma, Cushings syndrome, or
post-menopausal osteoporosis show decreased osteoblast recruit-
ment and bone formation [12,14,16], and second, proliferation
and osteoblast differentiation markers support that the canopy is
an important reservoir of osteoblast progenitors during remodel-versal phase in ODN- and ALN-treated rabbits. (A) The proximity of reversal surfaces
rabbits treated with vehicle (Veh), alendronate (ALN), or odanacatib (ODN). Data are
as deﬁned in the methods. Horizontal bars indicate mean values. Overall differences
For each OVX rabbit treated with ALN (grey diamonds) or ODN (black triangles) the
lotted against the proportion of bone surface covered by osteoclasts under canopies
e rabbits according to the presence of a high or low extent of BS covered by OC under
it put at 50%). The limits are indicated by the dotted lines. The relationship between
bol represents the measurement done in one rabbit.
Fig. 4. Model proposing the osteoclast-canopy interface as the physical site
coupling bone resorption to bone formation. According to this model, the osteoclast
has two polarized functional domains: (i) the apical one (corresponding to the
rufﬂed border) is catabolic and directed against the bone matrix to be solubilized;
(ii) the basolateral one (corresponding to the secretory domain which releases the
osteoclast products transported through transcytosis [22,23,25]) is anabolic and
oriented towards the canopy cells described in [12]. The canopy cells are a reservoir
of osteoprogenitors differentiating into mature bone forming osteoblasts during the
bone remodeling cycle [11]. Note the strategic position of the canopy cells, which
makes them the ideal target cells for the factors released by the osteoclast. The
present data show that ODN increases the interface between osteoclasts and
canopy cells, which is expected to favor the exposure of the canopy cells to the
anabolic factors of the osteoclast. In contrast, ALN released by the osteoclast [20]
poisons the canopy cells, and, as shown here, leads to a reduction in the extent of
canopy coverage above osteoclasts – which is expected to reduce their exposure to
the anabolic factors of the osteoclast. For further explanations, see text.
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canopy cells to induce osteoblastogenesis has not been identiﬁed.
The interest of the present ﬁndings is to integrate the knowl-
edge provided by these two lines of research: our ﬁndings indicate
(1) that the osteoclasts may be the previously unrecognized trig-
gers inducing osteoblastogenesis in the canopy cells, and (2) that
the canopy cells might well be the previously unrecognized target
for the osteoclastic osteogenic factors. In this way osteoclasts and
canopy cells appear as partners in the coupling mechanism, and
the osteoclast-canopy interface appears the central physical place
where coupling occurs. This concept is illustrated in Fig. 4. Further
studies are however necessary to investigate the presence of recep-
tors for osteoclastic anabolic factors in the canopy cells. In this
respect, it is of interest that we identiﬁed uPARAP/Endo 180 both
in the canopy cells and in the cells recruited on the eroded bone
surfaces. This collagen receptor was found to play a role in bone
formation [18] and in cell migration [28], and to participate in
the chemotactic response of osteoblast lineage cells to collagen
[29]. Immunostainings performed on human bone also showed
TRAcP in canopy cells (unpublished), supporting the hypothesis
that they take up osteoclast products.
The present ﬁndings also help understanding the intriguing
question why ODN and ALN, which inhibit equally well bone
resorption, affect bone formation differently. Our earlier analysis
suggested that this difference results from distinct effects of ODN
and ALN on the reversal phase [7]. Here we propose that within
the reversal phase, it is speciﬁcally the osteoclast-canopy interface
that is differently affected by ALN and ODN, thereby affecting the
osteoblast recruitment, which is critical for bone formation.
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